MENARA TA ONE, 22 JALAN P. RAMLEE, 50250 KUALA LUMPUR, MALAYSIA TEL: +603-20721277 / FAX: +603-20325048

Wednesday, August 26, 2015 FBM KLCI: 1,563.94

Sector: Healthcare

Karex Berhad

Back on Track

THIS REPORT IS STRICTLY FOR INTERNAL CIRCULATION ONLY*

TP: RM4.00 (+25.4%)

Last traded: RM3.22

BUY

Wilson Loo Tel: +603-2167 9606 wilsonloo@ta.com.my www.taonline.com.my

Review

- Karex released its FY15 results of RM60.0mn (+14.2% QoQ, +32.7% YoY). This was within ours (98.4%) and consensus (99.6%) expectations.
- Compared to FY14, revenue and PBT for FY15 grew to RM297.4mn (4.2% YoY) and RM73.9mn (+35.8% YoY) respectively. PBT margins have widened by 5.8p.p. to 24.8%. This expansion was due to, 1) sale of higher margin products, 2) stronger USD/RM (+17.4% YoY) and 3) low raw material costs. As a reference, local latex prices in FY15 have been relatively subdued, averaging at RM4.12/kg, compared to FY14 at RM5.11/kg.
- Sequentially, 4QFY15 revenue increased by 10.5% QoQ to RM78.9mn. This was attributed to the higher volume of condoms sold. Operating margin have improved by 1.4p.p. to 24.7%. This was also due to the sale of higher margin products, and favourable USD/Ringgit and raw material costs.

Outlook

- Moving forward, Karex would see an additional capacity of 3.0bn condoms p.a. coming from its new plants in Hat Yai, Thailand (+1.0bn) and Pontian, Johor (+2.0bn). These would bring total capacity to 7.0bn condoms p.a. The Hat Yai plant is slated for commissioning in September 2015 while the Pontian plant will be in December 2016. From our recent company visit, management shared that it has plans to expand its catheter segment, possibly doubling its existing capacity of 8.0mn, which is running at almost full capacity.
- In line with its strategy to grow its OBM segment, Karex had recently entered into a conditional share purchase agreement to purchase Medical-Latex (DUA) S/B, a local condom manufacturer based in Senai, Johor. This acquisition which is expected to be completed by early October 2015, would allow Karex to expand its existing array of brands. Besides this, come October 2015, Karex will be launching its ONE brand condoms in Malaysia and Singapore.

Impact

We make no changes to our estimates pending an Analysts' Briefing later today.

Valuation

Increase our TP for Karex to RM4.00/share (from RM3.60/share previously). This is based on a higher PE multiple of 29x. We are upbeat on 1) the potential synergies to be extracted from imminent M&A activities, 2) its strategy of increasing contributions from the higher margin OBM segment and 3) high ROE. Maintain our BUY recommendation on the stock.

| Share Information | |
|----------------------------------|-------------|
| Bloomberg Code | KAREX MK |
| Stock Code | 5247 |
| Listing | Main Market |
| Share Cap (mn) | 668.3 |
| Market Cap (RMmn) | 2,151.8 |
| Par Value | 0.25 |
| 52-wk Hi/Lo (RM) | 3.68/1.76 |
| 12-mth Avg Daily Vol ('000 shrs) | 1099.0 |
| Estimated Free Float (%) | 34.4 |
| Beta | 1.0 |
| Major Shareholders (%) | |

Karex One Ltd - 31.8 Lam Yiu Pang Albert - 6.4

| Forecast Revision | | |
|-----------------------|---------|-----------|
| | FY16 | FY17 |
| Forecast Revision (%) | - | - |
| Net profit (RMm) | 80.6 | 103.1 |
| Consensus | 84.7 | 104.2 |
| TA's / Consensus (%) | 95.1 | 98.9 |
| Previous Rating | Buy (Ma | intained) |

| Financial Indicators | | |
|----------------------|----------|----------|
| | FY16 | FY17 |
| Net gearing (x) | Net cash | Net Cash |
| CFPS (RM) | 0.1 | 0.1 |
| P/CFPS (x) | 34.5 | 23.8 |
| ROAA (%) | 14.6 | 15.7 |
| ROAE (%) | 17.6 | 19.6 |
| NTA/Share (RM) | 0.7 | 0.8 |
| Price/ NTA (x) | 4.6 | 3.9 |

| Scorecard | | |
|--------------|---------|--------|
| | % of FY | |
| vs TA | 98.4 | Within |
| vs Consensus | 99.6 | Within |

| Share Performance (%) | | |
|-----------------------|-------|----------|
| Price Change | KAREX | FBM KLCI |
| 1 mth | -0.3 | -9.1 |
| 3 mth | 6.6 | -11.5 |
| 6 mth | 14.7 | -13.9 |
| 12 mth | 64.3 | -16.0 |

(12-Mth) Share Price relative to the FBM KLCI





Table 1: Earnings Summary (RMmn)

| FYE Jun 30 | FY14* | FY15 | FY16F | FY17F | FY18F |
|-----------------------------|-------|-------|-------|-------|-------|
| Revenue | 285.3 | 297.4 | 407.3 | 492.1 | 581.0 |
| EBITDA | na | 71.7 | 116.1 | 147.1 | 156.1 |
| Depreciation & amortisation | na | 0.0 | -15.1 | -18.7 | -18.8 |
| EBIT | 55.2 | 71.7 | 100.9 | 128.4 | 156.1 |
| Net finance cost | -0.8 | 2.2 | 0.9 | 1.7 | 2.7 |
| EI | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| PBT | 54.4 | 73.9 | 101.8 | 130.1 | 158.8 |
| Taxation | -9.3 | -13.8 | -20.4 | -26.0 | -31.8 |
| MI | 0.0 | -0.1 | -0.8 | -1.0 | -1.3 |
| Net profit | 45.2 | 60.0 | 80.6 | 103.1 | 125.8 |
| Core net profit | 45.2 | 60.0 | 80.6 | 103.1 | 125.8 |
| EPS (sen) | 6.8 | 9.0 | 12.1 | 15.4 | 18.8 |
| EPS growth (%) | 55.6 | 32.7 | 34.5 | 27.8 | 22.0 |
| DPS (sen) | 2.5 | 2.3 | 3.0 | 3.9 | 4.7 |
| Dividend yield (%) | 0.8 | 0.7 | 0.9 | 1.2 | 1.5 |
| PER (x) | 47.6 | 35.9 | 26.7 | 20.9 | 17.1 |

^{*} estimated consolidated results

Table 2: FY15 Results Analysis (RMmn)

| | 14010 2.1 1 10 110 4100 11141 join (14 11111) | | | | | | | |
|----------------------------------|---|------|------|-------|-------|-------|-------|-------|
| FYE June | 4Q14 | 3Q15 | 4Q15 | % QoQ | % YoY | FY14 | FY15 | % YoY |
| Revenue | 63.1 | 71.4 | 78.9 | 10.5 | 25.0 | 285.3 | 297.4 | 4.2 |
| Result from operating activities | 13.8 | 16.7 | 19.5 | 17.0 | 41.9 | 55.2 | 71.7 | 29.9 |
| PBT | 13.6 | 17.3 | 20.8 | 20.3 | 53.1 | 54.4 | 73.9 | 35.8 |
| PAT | 12.2 | 15.2 | 17.3 | 13.4 | 41.7 | 45.2 | 60.1 | 33.0 |
| MI | 0.0 | 0.0 | 0.1 | - | - | 0.0 | -0.1 | - |
| Profit attributable to owners | 12.2 | 15.2 | 17.4 | 14.2 | 42.3 | 45.2 | 60.0 | 32.7 |
| EPS (sen) | 1.8 | 2.3 | 2.6 | 13.4 | 41.7 | 6.8 | 9.0 | 33.0 |
| Margins | | | | % | % | | | % |
| Operating margin (%) | 21.8 | 23.4 | 24.7 | 1.4 | 2.9 | 19.4 | 24.1 | 4.8 |
| PBT margin (%) | 21.5 | 24.2 | 26.4 | 2.1 | 4.8 | 19.1 | 24.8 | 5.8 |
| Tax rate (%) | 10.3 | 11.9 | 16.9 | 5.0 | 6.7 | 17.0 | 18.7 | 1.7 |
| PAT margin (%) | 19.3 | 21.4 | 21.9 | 0.6 | 2.6 | 15.8 | 20.2 | 4.4 |

Disclaimer

The information in this report has been obtained from sources believed to be reliable. Its accuracy or completeness is not guaranteed and opinions are subject to change without notice. This report is for information only and not to be construed as a solicitation for contracts. We accept no liability for any direct or indirect loss arising from the use of this document. We, our associates, directors, employees may have an interest in the securities and/or companies mentioned herein.

for TA Securities Holdings Berhad (14948-M)

MENARA TA ONE, 22 JALAN P. RAMLEE, 50250 KUALA LUMPUR, MALAYSIA TEL: +603-20721277 / FAX: +603-20325048 (A Participating Organisation of Bursa Malaysia Securities Berhad)

Kaladher Govindan - Head of Research